In contrast, her poor response to IL-6 inhibitors and the suboptimal efficacy of corticosteroids is consistent with reports indicating that CAPS is primarily an IL-1β–driven disease (24). This evidence concerns the gene IL1B and cryopyrin-associated periodic syndrome.